瓦里安医疗宣布CEO继任计划 | Varian

瓦里安医疗宣布CEO继任计划

总裁兼首席运营官陶克瑞 (Chris Toth) 将领导瓦里安加入西门子医疗
首席执行官魏思韬 (Dow Wilson) 将退休,将担任合并后公司的特别顾问

加州帕洛阿托, 2021年3月2日—瓦里安医疗 (NYSE: VAR) 宣布,瓦里安首席执行官(CEO)魏思韬(Dow Wilson)将在瓦里安与西门子医疗 (Frankfurt: SHL) 合并完成后退休,魏思韬在瓦里安供职已超过16年。瓦里安总裁兼首席运营官陶克瑞(Chris Toth)将接任CEO,在交易完成后带领瓦里安医疗加入西门子医疗,直接向西门子医疗首席执行官孟天齐博士(Dr. Bernd Montag)汇报。

该交易预计将于2021自然年上半年完成,为支持瓦里安与西门子医疗的无缝整合,魏思韬将担任西门子医疗的特别顾问。

“我代表董事会,感谢魏思韬杰出的领导力和对瓦里安做出的巨大贡献,”瓦里安董事会主席Andrew Eckert表示,“自2012年担任首席执行官以来,魏思韬一直领导着团队定义癌症治疗的新时代。除了带领瓦里安在放射治疗领域的市场领导地位和创新领域赢得了巨大的提升,他还推进了将人工智能、机器学习和云解决方案应用到癌症治疗的进程。通过这一战略转型,在过去五年中瓦里安实现了两位数的增长并创造了4000个工作岗位,更重要的是,为全球数百万患者带来了更多获益。”

“我有幸能作为瓦里安首席执行官服务公司近十年,”魏思韬表示,“在对抗癌症的斗争中,我们取得了长足的进步,我们与西门子医疗的转型结合将让瓦里安加速实现我们的愿景——创造一个无惧癌症的世界。与这样才华横溢、专业敬业的团队一起工作是我职业生涯的亮点,我相信在陶克瑞的领导下,瓦里安将继续提升对患者的影响力,并在我们共同建立的强大基础上更进一步。我将永远是瓦里安的忠实支持者,期待在场外追随并见证团队在未来几年将取得的成就。”

“我感到很荣幸能带领瓦里安与西门子医疗一起开启这一令人兴奋的新篇章,”陶克瑞表示,“自从我加入瓦里安以来,在这20多年间我见证了瓦里安如何演进和成长,令人难以置信。与此同时,我们坚持不懈笃定信念——我们可以战胜癌症。魏思韬激励了团队全情投入并坚定不移践行瓦里安的使命,随着我们的前进,我相信这将继续推动我们公司在未来取得更大的成功。”

Forward-Looking Statements

Except for historical information, this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Varian's future orders and the anticipated impact of the COVID-19 pandemic on Varian's business; and any statements using the terms "could," "believe," "expect," "promising," "outlook," "should," "well-positioned," "will" or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varian's actual results to differ materially from those anticipated. Such risks and uncertainties include:  (1) the future impact of the COVID-19 pandemic on Varian's business, including but not limited to, the impact on its workforce, operations, supply chain, demand for products and services, and Varian's financial results and condition; (2) Varian's ability to successfully manage the challenges associated with the COVID-19 pandemic; (3) Varian's ability to achieve expected synergies from acquisitions; (4) risks associated with integrating recent acquisitions; (5) global economic conditions and changes to trends for cancer treatment regionally; (6) currency exchange rates and tax rates; (7) the impact of the Tax Cuts and Jobs Act; (8) the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; (9) recent and potential future tariffs or a global trade war; (10) demand for and delays in delivery of Varian's products; (11) Varian's ability to develop, commercialize and deploy new products; (12) Varian's ability to meet Food and Drug Administration (FDA) and other regulatory requirements, regulations or procedures; (13) changes in regulatory environments; (14) risks associated with Varian providing financing for the construction and start-up operations of particle therapy centers, challenges associated with commercializing Varian's Proton Solutions business; (15) challenges to public tender awards and the loss of such awards or other orders; (16) the effect of adverse publicity; (17) Varian's reliance on sole or limited-source suppliers; (18) Varian's ability to maintain or increase margins; (19) the impact of competitive products and pricing; (20) the potential loss of key distributors or key personnel; (21) challenges related to entering into new business lines; (22) the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement; (23) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the transaction; (24) risks related to disruption of management's attention from Varian's ongoing business operations due to the transaction; (25) the effect of the announcement of the transaction on the ability of Varian to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (26) the ability to meet expectations regarding the timing and completion of the transaction; (27) risks associated with transaction-related litigation; and (28) the other risks listed from time to time in Varian's filings with the SEC.  For additional information concerning factors that could cause actual results and events to differ materially from those projected herein, please refer to Varian's Annual Report on Form 10-K for the year ended October 2, 2020 and subsequent Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.  Varian assumes no obligation to update or revise the forward-looking statements in this communication because of new information, future events, or otherwise.


Investor Relations Contact
Anshul Maheshwari
Vice President, Treasury and Investor Relations
+1 (650) 424-6081
investors@varian.com
 

Press Contact
Kathy Conner
Vice President, Global Corporate Marketing
+1 (650) 424-5695
kathy.conner@varian.com